About BIONOVO
BIONOVO is a Healthcare company based in Emeryville (United States) founded in 2002 by Mary Tagliaferri and Isaac Cohen. Botanically-derived drugs are developed for menopause and cancer treatments. BIONOVO has raised $16.35 million across 7 funding rounds from investors including HHS. The company has 190 employees. Its chief executive, as recorded, is Isaac Cohen. Its Indian entity Novorise Fintech India Private Limited reported revenue of ₹68.42 Cr. Its focus areas include Life Sciences, Women Health, Drugs and Sustainability Tech. Its competitors include Auxilium Pharmaceuticals, Agile Therapeutics and Marius Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Detailed information about BIONOVOs operations, sectors, or solutions is not available from the provided content. The website only includes a basic contact form with no specific data on business activities or offerings.
- Headquarters Emeryville, United States
- Employees 190
- Founders Mary Tagliaferri, Isaac Cohen
- SectorsHealthcare
- Website bionovo.com
- Social LinkedIn X
- Legal Name Novorise Fintech India Private Limited
- Date of Incorporation 01 Apr, 2019
- Jurisdiction Gurgaon, Haryana, India
- Indian entity revenue₹68.42 Cr
FY 2024 · +32% YoY
- Indian entity net profit₹3.18 Cr
FY 2024 · 5% margin
- Indian entity EBITDA₹5.57 Cr
FY 2024 · 8% margin
- Total Equity Funding$16.35M (USD)
in 7 rounds
- Latest Funding Round$374.1K (USD), Grant
Sep 2010
- Investors
- Employee Count190
Associated legal entities of BIONOVO
BIONOVO operates through Novorise Fintech India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Novorise Fintech India Private Limited CIN U74999HR2019FTC079493 | Active | 01 Apr 2019 | Gurgaon, Haryana | ₹68.4 Cr | 190 | 6 | View details |
Funding Insights of BIONOVO
BIONOVO has successfully raised a total of $16.35M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $374.1 thousand completed in September 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.35M
- Total Rounds 7
- Last Round Grant — $374,095
- First Round $465,352
(Jul 2006)
- Investors Count 1
All 7 funding rounds of BIONOVO with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in BIONOVO
BIONOVO has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for BIONOVO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Novorise Fintech India Private Limited (BIONOVO)
Novorise Fintech India Private Limited is the primary company behind BIONOVO. The board of Novorise Fintech India Private Limited currently have 6 directors; the longest-serving is Michael Vincent Rangel, appointed in 2019. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Michael Vincent Rangel DIN 08408968 | Director | 01 Apr 2019 | 7 yrs 7 mo | Novorise Fintech India Private Limited |
| Tyler Mc Intyre DIN 08408969 | Director | 01 Apr 2019 | 7 yrs 7 mo | Novorise Fintech India Private Limited |
| Hannan Munshi DIN 08687773 | Director | 04 Feb 2020 | 6 yrs 9 mo | Novorise Fintech India Private Limited |
| Maulik Mendapara DIN 10771381 | Director | 09 Sep 2024 | 2 yrs 1 mo | Novorise Fintech India Private Limited |
| Neha Kishore Chinai DIN 11279394 | Director | 04 Sep 2025 | 1 yr 2 mo | Novorise Fintech India Private Limited |
| Emily Chongwen Chiu DIN 11212083 | Additional Director | 04 Sep 2025 | 1 yr 2 mo | Novorise Fintech India Private Limited |
People of BIONOVO
2 people are tracked at BIONOVO (2 in leadership); the tracked headcount is 190.
| Name | Role | Group |
|---|---|---|
Mary Tagliaferri | Co-Founder | Leadership |
Isaac Cohen | Co-Founder & CEO | Leadership |
Complete people profiles for BIONOVO
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of BIONOVO
Figures of Novorise Fintech India Private Limited, the primary company behind BIONOVO, for FY 2024. Revenue was ₹68.42 Cr (+32% year on year). Net profit was ₹3.18 Cr (5% margin). EBITDA was ₹5.57 Cr (8% margin). Revenue has grown at a compounded annual rate of +134% over three years.
- ₹68.42 CrRevenue · FY 2024 · +32% YoY
- ₹3.18 CrNet profit · 5% margin
- ₹5.57 CrEBITDA · 8% margin
- ₹10 LakhPaid-up capital
- 190Employees (provident fund records)
- +134%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Novorise Fintech India Private Limited are on its company page.
Detailed financial statements for BIONOVO
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of BIONOVO
3 dated milestones of BIONOVO across 8 years, from founding to its latest funding, stage changes and deals.
- Founded BIONOVO is founded.
- Funding First funding round of $465K.
- Funding Latest funding round, Grant, of $374K.
Competitors of BIONOVO
BIONOVO has 3 listed competitors in our database, 3 of them funded. They include Auxilium Pharmaceuticals, Agile Therapeutics and Marius Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| auxilium.com | 1999 | Philadelphia, United States | $43M | Developer of therapeutics and drug-device combinations for urology and sexual health | ||
| agiletherapeutics.com | 1997 | Princeton, United States | $123.06M | Therapeutics for women's healthcare are developed and offered. | ||
| mariuspharma.com | 2017 | Raleigh, United States | $11.61M | A proprietary oral testosterone replacement therapy platform is developed. |
Detailed competitors of BIONOVO
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BIONOVO
Websites that share an audience with BIONOVO (bionovo.com).
Websites whose visitors overlap most with BIONOVO. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
nanotherapeutics.com | nanotherapeutics.com | 100% | – | ||
chemovation.com | chemovation.com | 100% | – | ||
| vicortech.com | 100% | View details | |||
| cytomyx.com | 100% | View details | |||
| prosidion.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for BIONOVO
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Women's Health & Fertility
3 companies that operate in the same segment as BIONOVO (Women's Health & Fertility) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | ||
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | 861 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bionovo
Complete news archive for BIONOVO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BIONOVO
BIONOVO was founded in 2002 and raised its 1st funding round 4 years after it was founded.
BIONOVO is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
Isaac Cohen is the CEO of BIONOVO, as recorded in our data. They have also founded this company.
BIONOVO is a funded company, having raised a total of $16.35M across 7 funding rounds to date. The company's 1st funding round was a Grant of $465.35K, raised on Jul 2006.
BIONOVO has 190 employees.
The primary company behind BIONOVO, Novorise Fintech India Private Limited, reported revenue of ₹68.42 Cr for FY 2024, up 32% year on year.
Detailed information about BIONOVOs operations, sectors, or solutions is not available from the provided content. The website only includes a basic contact form with no specific data on business activities or offerings.
BIONOVO's top competitors include Agile Therapeutics, Auxilium Pharmaceuticals and Marius Pharmaceuticals.
BIONOVO has 1 investor. Key investors include HHS.
BIONOVO operates through Novorise Fintech India Private Limited.
The legal entities of BIONOVO currently have 6 directors, including Hannan Munshi, Michael Vincent Rangel, Tyler Mc Intyre and others.